Centrexion Therapeutics

The company has a pipeline of clinical-stage non-opioid medicines for chronic pain, with drug candidates tailored to pain type and source.

Charles Oh, M.D., is Centrexion Therapeutics’ chief medical officer. He joined the company in September 2025 after more than 20 years in clinical development and medical affairs, and previously served as chief medical officer of Corium, LLC.

Mike Ward joined Centrexion Therapeutics as CFO in 2019. He has more than 25 years of experience, primarily as a life sciences investment banker and as CFO and CBO of public and private life sciences companies, including Bionano Genomics.

Niti Goel is a board-certified rheumatologist and physician-scientist with more than 25 years of industry experience. Goel consults for Centrexion, serves as president of Caduceus Biomedical Consulting, and has held senior leadership roles at TrialSpark (now Formation Bio), Abcuro, and Kezar Life Sciences.

Randall Stevens joined Centrexion Therapeutics as chief medical officer in April 2015 and led its clinical, medical, and regulatory operations through 2025. Stevens is a board-certified internist and rheumatologist with more than 25 years of experience in pharmaceutical medicine and previously led inflammation and immunology clinical development at Celgene Corporation.

Centrexion focuses on markets with unmet needs in pain and immunology.

The company says it is building a portfolio in non-opioid pain relief and immunology, led by experienced industry leaders.

This Privacy Policy was last updated on November 3, 2015.

Centrexion Therapeutics provides its website subject to its Terms of Use Agreement, which users agree to by accessing, browsing, or otherwise using the website.